Staining of antigen activated lymphocytes (SAAL): A highly specific method for flow cytometric quantitation of tumor-specific CD8+ T cells

Journal of Immunological Methods

Volumn 241, Issue 1-2, 2000, Pages 131-139

  Kowalczyk, Dariusz W ^a   Wlazlo, Anthony P ^a   Giles Davis, Wynetta ^a   Ertl, Hildegund C J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocytes; Detection method for CTLs; Interferon gamma; T cell activation; Tumor associated antigens

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTERMETHOD COMPARISON; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TECHNIQUE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHROMIUM RADIOISOTOPES; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; LYMPHOCYTE ACTIVATION; MICE; STAINING AND LABELING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034738719     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(00)00208-8     Document Type: Article

References (17)

1. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouh D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94.
2. 51Cr-labelled allogenic target cells in vitro; inhibition by isoantibody and by drugs. Immunology. 14:1968;181.
3. Foley E.J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13:1953;835.
4. Freedman L.R., Cerottini J.C., Brunner K.T. In vivo studies of the role of cytotoxic T-cells in tumor allograft immunity. J. Immunol. 109:1972;1371.
5. Grimm E.A., Mazumder A., Zhang H.Z., Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155:1982;1823.
6. Harvey M., Levine A.J. P53 alteration is a common event in the spontaneous immortalization of primary p53 embryo fibroblasts. Genes Dev. 5:1991;2375.
7. He Z., Wlazlo A.P., Kowalczyk D.W., Cheng J., Xiang Z.Q., Giles-Davis W., Ertl H.C.J. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 270:2000;146.
8. Lin K.-Y., Guarnieri F.G., Staveley-O'Carroll K.F., Levitsky H.I., August J.T., Pardoll D.M., Wu T.-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21.
9. MacDonald H.R., Cerottini J.C., Ryser J.E., Maryanski J.L., Taswell C., Widmer M.B., Brumner K.T. Quantitation and cloning of cytolytic T lymphocytes and their precursors. Immunol. Rev. 51:1980;93.
10. + T cells: a reevaluation of bystander activation during viral infection. Immunity. 8:1998;177.
11. Old L.J., Boyse E.A., Clarke D.A., Carswell E. Antigenic properties of chemically induced tumors. Ann. New York Acad. Sci. 101:1962;80.
12. Prehn R.T., Main J.M. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:1957;769.
13. Suni M.A., Picker L.J., Maino V.C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J. Immunol. Methods. 212:1998;89.
14. Townsend A., Ohlen C., Bastin J., Ljunggren H.G., Foster L., Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature. 340:1989;443.
15. Trinchieri G. Biology of natural killer cells. Adv. Immunol. 47:1989;187.
16. Vierboom M.P.M., Nijman H.W., Offringa R., van der Voort E.I.H., van Hall T., van den Broek L., Fleuren G.J., Kenemans P., Kast W.M., Melief C.J.M. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 186:1997;695.
17. Vierboom M.P., Feltkamp M.C., Neisig A., Drijfhout J.W., ter Schegget J., Neefjes J.J., Melief C.J., Kast W.M. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J. Immunother. 21:1998;399.